SEITO is dedicated to developing innovative immunotherapies for immune-mediated diseases, including autoimmune disorders, chronic inflammation, and transplant rejection. These conditions, which are both serious and lifelong, impact approximately 4% of the population in developed countries. Our approach focuses on engineering regulatory T (Treg) cell engagers (TREX) to precisely and safely activate Treg cells, helping to restore immune balance and prevent harmful self-targeted immune responses.
Company Details
- Employees
- 4
- Address
- Zurich, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.seitobio.ch/
- HQ
- Zurich
Seito Biologics Questions
Seito Biologics's website is https://www.seitobio.ch/
Seito Biologics's LinkedIn profile is https://ch.linkedin.com/company/seito-biologics-ag
Seito Biologics has
4 employees.
View email and phone details for 4
employees at Seito Biologics.
Seito Biologics's industry is
Biotechnology Research
Seito Biologics's top competitors are
Positrigo,
Basilea Pharmaceutica,
Apersys Ag,
Invirtuolabs,
Azurecell,
Secured Finance Ag,
Transheps,
Properti,
Novomof Ag,
Mosanna Therapeutics.
Seito Biologics's categories are Biotechnology Research
